Pure Global AI
NCT06335082Not yet recruiting

A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF

A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse Pulsed Field Ablation Technology for Atrial Fibrillation
Heart Rhythm Clinical and Research Solutions, LLCClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Atrial Fibrillation
Drug/Device/Intervention
Pulsed Field Ablation
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Location
Birmingham,Ventura,Glenview,Boston,Haddon Heights,Austin, United States of America
Timeline & enrollment
Phase
N/A
Start date
Apr 15, 2024
End date
Jan 30, 2027
Enrollment
900 participants
Primary outcome

Long term effectiveness,Long-term safety

Summary

The DISRUPT-AF Registry is an observational, prospective, multi-center, non-randomized,
 real-world registry designed to obtain clinical experience with the Farapulse Pulsed Field
 Ablation System for the treatment of atrial fibrillation (AF).

ICD-10 classifications
Chronic atrial fibrillationPersistent atrial fibrillationParoxysmal atrial fibrillationAtrial fibrillation and flutterAtrial fibrillation and atrial flutter, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06335082
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06335082 through Pure Global AI's free database. This phase not specified trial is sponsored by Heart Rhythm Clinical and Research Solutions, LLC and is currently Not yet recruiting. The study focuses on Atrial Fibrillation. Target enrollment is 900 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.